OncoMatch/Clinical Trials/NCT05642572
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Is NCT05642572 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Ramucirumab and Capmatinib for recurrent lung non-small cell carcinoma.
Treatment: Capmatinib · Osimertinib · Ramucirumab — This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and that has EGFR and MET gene changes. Capmatinib and osimertinib are in a class of medications called kinase inhibitors. They work by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop or slow the spread of cancer cells and may help shrink tumors. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Giving capmatinib, osimertinib, and/or ramucirumab and targeting abnormal gene changes in tumor cells may be effective in shrinking or stabilizing advanced non-small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR sensitizing mutation
Required: MET amplification
Disease stage
Required: Stage IV (AJCC v8)
Metastatic disease required
Stage IV Lung Cancer AJCC v8
Performance status
ZUBROD 0–1
Prior therapy
Must have received: EGFR tyrosine kinase inhibitor (osimertinib) — most recent line
radiologically or clinically progressed (in the opinion of the treating physician) on osimertinib, alone or in combination with other agent(s), as their most recent line of therapy
Cannot have received: VEGF inhibitor
must not have received an anti-VEGF or VEGFR inhibitor
Cannot have received: MET inhibitor
must not have received ... MET inhibitor
Cannot have received: any anti-cancer drug (except osimertinib)
Exception: osimertinib may continue up to the day prior to study treatment initiation
must not have received any anti-cancer drug (investigational or standard of care drug, except osimertinib) within 21 days prior to sub-study randomization
Cannot have received: radiation therapy
must not have received any radiation therapy within 14 days prior to sub-study randomization
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1.5 x 10^3/uL; Hemoglobin < 9.0 g/dL; Platelets ≥ 100 x 10^3/uL
Kidney function
serum creatinine ≤ institutional ULN OR calculated creatinine clearance ≥ 50 mL/min
Liver function
Total bilirubin ≤ 1.5 x institutional ULN unless history of Gilbert's disease (then ≤ 5 x ULN); AST and ALT ≤ 2.5 x institutional ULN (≤ 5 x ULN with liver metastasis)
Cardiac function
ECG with QTcF ≤ 470 msec; adequate cardiac function; NYHA class 2B or better if cardiac history
Absolute neutrophil count ≥ 1.5 x 10^3/uL ... Hemoglobin < 9.0 g/dL ... Platelets ≥ 100 x 10^3/uL ... Total bilirubin ≤ 1.5 x institutional ULN unless history of Gilbert's disease ... AST and ALT ≤ 2.5 x institutional ULN ... serum creatinine ≤ the IULN OR calculated creatinine clearance ≥ 50 mL/min ... ECG with QTcF ≤ 470 msec ... adequate cardiac function ... NYHA class 2B or better
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Katmai Oncology Group · Anchorage, Alaska
- Kingman Regional Medical Center · Kingman, Arizona
- Cancer Center at Saint Joseph's · Phoenix, Arizona
- Illinois CancerCare-Carthage · Carthage, Illinois
- Centralia Oncology Clinic · Centralia, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify